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and, induced mitotic catastrophe in the most sensitive cell lines U87MGLuc 
and E2. These events were apoptosis-independent. Combination with IR 
increased GSC cell death in the two GSC models tested to date. Accumu-
lation of cells in mitosis following ME-344 treatment was recapitulated in 
orthotopic GBM xenografts in vivo, although few mitotic catastrophe events 
were observed 24 h after treatment. ME-344 demonstrated therapeutic effi-
cacy as a single agent in U87MGLuc2 orthotopic xenografts by extend-
ing mouse survival compared to vehicle (p=0.043). CONCLUSION: Two 
agents that induce mitosis through different mechanisms have promising 
single agent activity against all GBM cell lines tested in vitro and in vivo. 
Further preclinical evaluation in combination with IR and/or temozolomide 
is underway. Results indicate that this therapeutic strategy for GBM has 
clinical potential.
OS1.5 HARNESSING SOLUBLE LRIG1 FOR PAN-RTK TARGETING 
IN GLIOBLASTOMA
V. Neirinckx1, A. Schuster1, A. Chevigné1, M. H. H. Schmidt2,3, S. 
P. Niclou1,4; 1Luxembourg Institute of Health, Luxembourg, Luxembourg, 
2Johannes Gutenberg University, Mainz, Germany, 3German Cancer 
Research Center (DKFZ), Heidelberg, Germany, 4KG Jebsen Brain Tumour 
Research Center, Bergen, Norway.
INTRODUCTION: The role of receptor tyrosine kinases (RTKs) in glio-
blastoma is widely acknowledged. However, therapies based on RTK tar-
geting have been continuously unsuccessful in GBM patients, highlighting 
the complexity of RTK signaling and biology. LRIG1 (Leucine-rich Repeats 
and ImmunoGlobulin domains protein 1) was identified as an endogenous 
inhibitor of epidermal growth factor receptor (EGFR) and other RTKs, and 
was confirmed as a tumor suppressor in various cancer types. We previ-
ously identified the soluble form of LRIG1 as a potent inhibitor of GBM 
growth in vivo, irrespective of EGFR status. Here, we aim to shed light on 
the molecular mechanisms underlying its anti-cancer activity. MATERIAL 
AND METHODS: We used GBM cells overexpressing EGFRvIII, with or 
without soluble LRIG1 overexpression. In parallel, we generated a recom-
binant human soluble LRIG1 protein (rh-sLRIG1) by expressing LRIG1 
ectodomain in insect cells via baculovirus infection and subsequent His-
tag purification. rh-sLRIG1 was applied in the medium of classical GBM 
cell lines and patient-derived GBM stem-like cells. Applying a variety of 
cell-based assays, cell proliferation, migration, cell morphology, as well 
as protein expression and protein-protein interactions were investigated. 
RESULTS: We confirmed that sLRIG1 efficiently reduced proliferation and 
invasion capacities of GBM cells, and modulated cytoskeleton proteins and 
cell shape. Inhibition of cell proliferation by sLRIG1 was independent of 
EGFR expression levels in GBM cells and interestingly, rh-sLRIG1 treatment 
was associated with downregulation of AXL, which constitutes a newly-
identified regulatory function of LRIG1. We are currently addressing the 
impact of the LRIG1-AXL signaling axis on GBM invasion and resistance to 
EGFR inhibition. CONCLUSION: We identified AXL as a novel LRIG1 tar-
get and provide evidence for the potential therapeutic application of recom-
binant sLRIG1 in the inhibition of growth factor signaling in GBM.
OS1.6 CHARACTERIZING THE OVER-EXPRESSION OF YKI/
YAP/TAZ TRANSCRIPTION FACTORS IN GLIOMAGENESIS AND 
RESULTS OF A PHASE 0 CLINICAL TRIAL FOR A PROPOSED NOVEL 
TREATMENT OF GLIOBLASTOMAS
K. Vigneswaran, S. Oh, S. Lallani, R. Read, J. Olson; Emory University 
School of Medicine, Atlanta, GA, United States.
BACKGROUND: Glioblastomas (GBMs) harbor frequent genetic lesions 
that include amplification, mutation, and/or over expression of receptor 
tyrosine kinases (RTKs). Using a novel kinome wide RNAi screen we identi-
fied the Hippo kinase pathway and it downstream targets, Yki-YAP/TAZ 
transcription factors, as tumor enhancers in gliomagenesis. YAP/TAZ pro-
mote the initiation and progression of other tumor types and several pub-
lished studies show that pharmacologic inhibition of YAP and TAZ with 
the drug verteporfin (VP) blocks tumor cell growth. Thus, we hypothesize 
that, because of RTK mutations, YAP/TAZ become overexpressed and acti-
vated to constitutively drive a TEAD-dependent gene expression program 
that provokes an uncontrolled expansion of RTK-PI3K mutant neural stem/
progenitor cells to create malignant glial tumors. MATERIAL AND METH-
ODS: We tested VP in vitro on genotyped neurosphere cultures which were 
assessed for self-renewal, proliferation, and survival using neurosphere for-
mation and WST-1 assays. To confirm that VP inhibits expression of YAP/
TAZ-TEAD transcriptional targets, we performed experiments and har-
vested RNA for RNAseq, qPCR, and completed western blots and ChIP 
analysis. In-vivo experiments were carried out in murine xenografts bear-
ing YAP/TAZ-expressing GBM that were used to make organotypic slice 
cultures which were treated with VP and assayed for tumor growth and 
cell survival. A Phase 0 clinical trial was designed to determine VP bioavail-
ability. Because VP has virtually the same excitation and emission spectra 
as protoporphyrin IX, we administered VP to patients prior to surgery and 
used fluorescence-assisted microscopy to determine if VP is visible in tumors. 
On encountering tumor intraoperatively, the operative microscopy system 
was used to illuminate the tumor bed with blue light (400–410 nm), and 
photographs were taken through the microscope using a camera adapted for 
imaging in the red (620–700 nm) emissions spectrum. Resected tumor tissue 
remaining after satisfying clinical goals was sent for ex vivo research ana-
lysis. RESULTS: Our data reveal that YAP and TAZ become overexpressed 
in tumor cells with RTK mutations, and that YAP/TAZ drive brain tumor 
cell growth and progression by up-regulation of novel RTK genes including 
EGFR. VP treatment knocks down target gene transcription, protein levels, 
leads to cell death and halts tumor progression. VP extraction from tumor 
tissue and fluoroscopic examination show successful drug uptake from all 
patients in a Phase 0 clinical trial. CONCLUSION: We believe that as a 
consequence of RTK mutations, YAP/TAZ becomes over-expressed in glio-
mas and constitutively drive a TEAD-dependent gene expression program 
that provokes an uncontrolled expansion of RTK -PI3K mutant neural stem/
progenitor cells to create malignant glial tumors that can be treated with VP 
which shows bioavailability in glioblastomas.
OS1.7 GENOMIC ATTRIBUTES OF TUMOR EVOLUTION AND 
TREATMENT RESPONSE IN DIFFUSE GLIOMA
A. L. Lin, P. Jonsson, S. Ogilvie, S. Chavan, C. Nolan, I. Gavrilovic, 
T. Kaley, C. Grommes, E. Pentsova, E. Diamond, M. Daras, J. Stone, 
L. DeAngelis, V. Tabar, C. Brennan, R. J. Young, M. Rosenblum, B. 
S. Taylor, I. K. Mellinghoff; Memorial Sloan Kettering Cancer Center, New 
York, NY, United States.
BACKGROUND: Though the genomic landscape of primary gliomas has 
been well characterized by The Cancer Genome Atlas, the genetic determi-
nants of malignant transformation and response to therapy remains poorly 
understood. MATERIAL AND METHODS: Prospective clinical sequencing 
was performed on 1,004 gliomas from 923 patients. This dataset includes 
primary and recurrent tumors and contains detailed clinical annotation, 
including review of the patients’ imaging. RESULTS: We investigated the 
germline and somatic attributes of IDH1/2-wildtype and IDH1/2-mutant 
tumors at the time of diagnosis and recurrence. 13% of patients harbored 
either a pathogenic or likely pathogenic germline mutation, whereof 29% 
arose in genes mediating DNA repair. In astrocytomas, agnostic of IDH 
status, cell cycle alterations were depleted in low-grade tumors. Moreover, 
mutations in effectors of the cell cycle were associated with the development 
of enhancing disease in IDH-mutant astrocytomas but not oligodendroglio-
mas. IDH-mutant astrocytomas with a cell-cycle alteration have a signifi-
cantly shorter progression-free survival from recurrence compared to tumors 
without a cell cycle alteration (median 2. 5 vs. 35. 3 months, HR 3. 25, log-
rank p-value 0. 00061). Based on our data, hypermutation appears to occur 
exclusively in the context of pre-existing cell cycle alterations in astrocytic 
tumors, regardless of IDH status. We next correlated molecular findings with 
clinical behavior and treatment response and defined subsets of gliomas that 
are uniquely susceptible to targeted treatment and have a differential prog-
nosis. CONCLUSION: Cell-cycle alterations are lineage-specific alterations 
associated with aggressive disease in glioma. Targeted genomic sequencing 
can identify subsets of tumors with a greater sensitivity to treatment and a 
better prognosis.
OS2 NON-SURGICAL TREATMENT
OS2.1 OBJECTIVE RESPONSES TO CHEMOTHERAPY IN 
RECURRENT GLIOMA DO NOT PREDICT BETTER SURVIVAL: 
A PROSPECTIVE ANALYSIS FROM THE GERMAN GLIOMA 
NETWORK
O. Bähr1, B. Hentschel2, E. Hattingen3, M. Reusche2, M. Tatagiba4, 
J. Tonn5, O. Schnell6, G. Schackert7, M. Westphal8, U. Herrlinger3, 
T. Pietsch3, G. Reifenberger9, M. Weller10, M. Löffler2, J. P. Steinbach1; 
1University Hopsital Frankfurt, Frankfurt, Germany, 2University Leipzig, 
Leipzig, Germany, 3University Hopsital Bonn, Bonn, Germany, 4University 
Hopsital Tübingen, Tübingen, Germany, 5University Hopsital Munich 
(LMU), Munich, Germany, 6University Hopsital Freiburg, Freiburg, 
Germany, 7University Hopsital Dresden, Dresden, Germany, 8University 
Hopsital Hamburg (UKE), Hamburg, Germany, 9University Hopsital 
Düsseldorf, Düsseldorf, Germany, 10University Hopsital Zurich, Zurich, 
Germany.
BACKGROUND: Outside of clinical trials, the occurrence of object-
ive responses (OR) to chemotherapy in patients with recurrent gliomas is 
poorly characterized. Further, the predictive value of OR for progression-
free survival (PFS) and overall survival (OS) in glioma patients is unclear. 
MATERIAL AND METHODS: We screened the German Glioma Network 
Database for patients who had received any chemotherapy for recurrent 
glioma from 2004–2008. Patients with a prior gross total resection of the 
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